The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes

Mol Immunol. 2006 Feb;43(6):643-51. doi: 10.1016/j.molimm.2005.04.006.

Abstract

The modulation the specific, adaptive immune response by complement, particularly of by complement C3, is mainly attributed to its interaction with complement receptors on B-lymphocytes. The function of complement receptors on T-lymphocytes, in contrast, is less well understood, although expression of the complement receptor (CR)1 and CR3 on T-cells has been described years ago. In the present study we investigated the effect of antibodies to CR1 on T-cell lines and peripheral T-cells of healthy donors, respectively. Antibodies to CR1 profoundly inhibited the proliferation of the T-cells; of note is, that exogenously added interleukin 2, though enhancing proliferation, did not overcome the inhibitory effect mediated by anti-CR1. While anti-CR1 had no effect on the activation of the immediate early genes c-jun or c-fos nor on the early increase of gamma interferon- or interleukin 2-specific RNA, the protein synthesis of those cytokines was inhibited. Moreover, synthesis of the proliferating cell nuclear antigen (PCNA) was reduced as was the expression of cyclins, particularly of cyclin A and cyclin D3. Taken together, the data indicate that triggering CR1 inhibits proliferation of T-lymphocytes by a mechanism operating downstream of the initial signalling events.

MeSH terms

  • Cell Cycle
  • Cell Proliferation*
  • Cells, Cultured
  • Cyclins / biosynthesis
  • Genes, Immediate-Early
  • Humans
  • Interferon-gamma / biosynthesis
  • Interleukin-2 / biosynthesis
  • Interleukin-2 / pharmacology
  • Proliferating Cell Nuclear Antigen / biosynthesis
  • Receptors, Complement 3b / physiology*
  • Signal Transduction*
  • T-Lymphocytes / cytology*

Substances

  • Cyclins
  • Interleukin-2
  • Proliferating Cell Nuclear Antigen
  • Receptors, Complement 3b
  • Interferon-gamma